ForPatients

by Roche

Chronic Lymphocytic Leukemia

A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities

Trial Status Trial Runs In Trial Identifier
Terminated 5 Countries NCT02336048 2014-004594-16
BO29448

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This multicenter, double-blind, randomized, placebo-controlled study will evaluate the safety of a single infusion of tocilizumab versus placebo, administered in addition to standard premedications (antipyretic, antihistamine, and corticosteroid) prior to the first infusion of obinutuzumab administered in combination with oral chlorambucil to participants with previously untreated B-CLL who have comorbidities. All eligible participants will be treated with a total of 6 cycles of obinutuzumab + chlorambucil (cycle length = 28 days).

Hoffmann-La Roche Sponsor		Phase 1 Phase	
NCT02336048 2014-004594-16 BO29448 Trial Identifiers			
Eligibility Criter	ia:		
Gender All	Age >= 18 Years	Healthy Volunteers No	